GlassScriptPhysician profile
Shikha Bharaktiya
NPI 1467460139
$70,476.37
in general payments reported to CMS, 2019-2025
45 companies · $7,364 in 2025
The $7,364 reported for 2025 was more than what 89% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,493 · 2020: $9,768 · 2021: $5,145 · 2022: $19K · 2023: $11K · 2024: $17K · 2025: $7,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $8,000 · Honoraria: $2,700 · Travel and Lodging: $1,878 · Consulting Fee: $1,383 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $21,016.91 |
| Food and Beverage | $8,000.00 |
| Honoraria | $2,700.00 |
| Travel and Lodging | $1,877.79 |
| Consulting Fee | $1,382.50 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $48,298.94 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Madrigal Pharmaceuticals | $4,440.95 | 2024-2025 | Rezdiffra, Resmetirom |
| Zealand Pharma US, INC. | $3,584.81 | 2020-2022 | |
| Corcept Therapeutics | $2,274.70 | 2024-2025 | Korlym |
| Cequr Corporation | $2,213.79 | 2025 | Cequr Simplicity |
| Lilly USA, LLC | $1,062.09 | 2019-2025 | Jardiance, Mounjaro, Baqsimi |
| Ascensia Diabetes Care US INC. | $1,056.36 | 2023-2025 | |
| Senseonics, Incorporated | $800.00 | 2024-2025 | Eversense |
| Sanofi-Aventis U.S. LLC | $669.63 | 2019-2025 | |
| Amneal Pharmaceuticals LLC | $604.66 | 2020-2025 | Unithroid |
| Abbott Laboratories | $539.23 | 2019-2025 | Freestyle Libre 3 |
| Abbvie INC. | $452.39 | 2019-2025 | Synthroid |
| Beta Bionics, INC. | $379.11 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Radius Health, INC. | $367.96 | 2019-2025 | Tymlos |
| Valeritas, INC. | $342.36 | 2019 |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $323.71 | 2019-2025 | Tepezza |
| Tandem Diabetes Care, INC. | $307.80 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Ibsa Pharma INC. | $281.45 | 2019-2024 | Tirosint, Licart, Tirosint |
| Dexcom, INC. | $279.73 | 2019-2025 | Dexcom G6 Transmitter |
| Mannkind Corporation | $228.65 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.58 | 2019-2024 | Jardiance, Tradjenta |
| Insulet Corporation | $195.46 | 2019-2020 | |
| Xeris Pharmaceuticals, INC. | $184.72 | 2021-2025 | Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $134.17 | 2024-2025 | Yorvipath |
| Astrazeneca Pharmaceuticals LP | $125.97 | 2020-2022 | |
| Currax Pharmaceuticals LLC | $96.98 | 2020-2025 | Contrave |
| Alexion Pharmaceuticals, INC. | $92.63 | 2021-2025 | Strensiq |
| Vivus LLC | $90.04 | 2019-2021 | |
| Becton, Dickinson and Company | $89.31 | 2021-2022 | |
| Sequel Med Tech, LLC | $87.31 | 2025 | Twiist |
| Acella Pharmaceuticals, LLC | $87.05 | 2024-2025 | NP Thyroid 60 |
| Merck Sharp & Dohme LLC | $65.20 | 2019-2021 | |
| Embecta Corp. | $58.02 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.88 | 2022-2023 | Cycloset |
| Avvisto Therapeutics, LLC | $55.70 | 2025 | Cycloset |
| Shire North American Group INC | $51.95 | 2019 | |
| Recordati_rare_diseases_inc. | $46.41 | 2025 | Isturisa |
| Amphastar Pharmaceuticals, INC. | $43.14 | 2025 | |
| Antares Pharma, INC. | $43.00 | 2021-2022 | |
| Astellas Pharma US INC | $38.60 | 2023 | Veozah |
| Ultragenyx Pharmaceutical INC. | $34.95 | 2024 | Crysvita |
| Kyowa Kirin, INC. | $28.61 | 2024 | Crysvita |
| Boston Scientific Corporation | $24.67 | 2020 | |
| Medtronic Minimed, INC. | $18.90 | 2020 | |
| Janssen Pharmaceuticals, INC | $13.80 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shikha Bharaktiya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.